Comments
Loading...
Elicio Therapeutics Analyst Ratings and Price Targets | NASDAQ:ELTX | Benzinga
Elicio Therapeutics Inc has a consensus price target of $9.5 based on the ratings of 3 analysts. The high is $10 issued by HC Wainwright & Co. on April 2, 2025. The low is $9 issued by Jones Trading on October 31, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Jones Trading, and HC Wainwright & Co. on April 2, 2025, October 31, 2024, and August 23, 2024, respectively. With an average price target of $9.67 between HC Wainwright & Co., Jones Trading, and HC Wainwright & Co., there's an implied 83.08% upside for Elicio Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Jones Trading
1calculated from analyst ratings
Analyst Ratings for Elicio Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/02/2025 | Buy Now | 89.39% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 10/31/2024 | Buy Now | 70.45% | Jones Trading | Soumit Roy32% | → $9 | Initiates | → Buy | Get Alert |
| 08/23/2024 | Buy Now | 89.39% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 06/06/2024 | Buy Now | 89.39% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/22/2024 | Buy Now | 89.39% | HC Wainwright & Co. | Robert Burns43% | $10 → $10 | Reiterates | Buy → Buy | Get Alert |
| 05/01/2024 | Buy Now | 89.39% | HC Wainwright & Co. | Robert Burns43% | $11 → $10 | Maintains | Buy | Get Alert |
| 04/01/2024 | Buy Now | — | Oppenheimer | Matthew Biegler37% | — | Reiterates | Perform → Perform | Get Alert |
| 01/17/2024 | Buy Now | 108.33% | HC Wainwright & Co. | Robert Burns43% | $10 → $11 | Maintains | Buy | Get Alert |
| 10/26/2023 | Buy Now | 127.27% | HC Wainwright & Co. | Robert Burns43% | → $12 | Assumes | → Buy | Get Alert |
FAQ
What is the target price for Elicio Therapeutics (ELTX) stock?
The latest price target for Elicio Therapeutics (NASDAQ:ELTX) was reported by HC Wainwright & Co. on April 2, 2025. The analyst firm set a price target for $10.00 expecting ELTX to rise to within 12 months (a possible 85.87% upside). 5 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Elicio Therapeutics (ELTX)?
The latest analyst rating for Elicio Therapeutics (NASDAQ:ELTX) was provided by HC Wainwright & Co., and Elicio Therapeutics reiterated their buy rating.
When was the last upgrade for Elicio Therapeutics (ELTX)?
There is no last upgrade for Elicio Therapeutics
When was the last downgrade for Elicio Therapeutics (ELTX)?
There is no last downgrade for Elicio Therapeutics.
When is the next analyst rating going to be posted or updated for Elicio Therapeutics (ELTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elicio Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elicio Therapeutics was filed on April 2, 2025 so you should expect the next rating to be made available sometime around April 2, 2026.
Is the Analyst Rating Elicio Therapeutics (ELTX) correct?
While ratings are subjective and will change, the latest Elicio Therapeutics (ELTX) rating was a reiterated with a price target of $10.00 to $10.00. The current price Elicio Therapeutics (ELTX) is trading at is $5.38, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
